Over a third (36%) of respondents’ staff have asked for faster digital technology systems.
News
Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
ABPI publishes new guidelines on pharma working with patients
The sourcebook covers six topics, which were identified as areas where further guidance would be of assistance.
Gilead, AbCellera team up against infectious diseases
AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties.
Pixuvri approved for use in EU
The drug has been granted the conversion of the conditional approval into standard marketing authorisation as a single agent.
AZ’ Farxiga shows 47% reduction in kidney function decline
The SGLT2 inhibitor was evaluated in 17,160 patients with type II diabetes.
Invokana hits endpoints in cardiovascular trial
A sub-group analysis found that the Janssen drug provided consistent CV and renal protection.
Strive for success in the 2019 Medical & Scientific Excellence Awards
This competition aims to honour those with exceptional talent within the medical and scientific industry, by offering a platform for candidates to share best practice and prove they’ve got the skills to be successful.
Boehringer, Lilly present positive Trajenta results at ADA
The study is the only active-comparator cardiovascular outcome trial for a DPP-4 inhibitor.
Cosentyx shows efficacy in key manifestations of psoriatic arthritis
The data will be presented at the Annual European Congress of Rheumatology (EULAR) on 12-15 June in Madrid, Spain.
Veeva announce new products at annual R&D Summit
The Vault is a content management system and suite of applications specifically built for life sciences that eradicates the need for multiple programmes.
Communications Team of the Year Chair explains what makes the 2019 competition such a unique experience
The new Chair of the 2019 PharmaTimes Communications Team of the Year executive steering group (ESG) reveals why in-house practitioners and agencies should enter into this unique, industry renowned competition.
Imfinzi, Opdivo among latest SMC decisions
The SMC published advice accepting five new medicines.
Provention’s PRV-031 found to delay type II diabetes by two years
A single 14-day course of PRV-031 was found to significantly delayed the onset and diagnosis of clinical type I diabetes.
